Associated Papers
Characterization of the mutational status of glioblastoma and high-grade astrocytomas in a Latin American cohort.
Fernández-Gajardo R et al.
Scientific Reports, 2025
41044136 (PubMed )
Supplement: 41598_2025_6129_MOESM1_ESM.xlsx › Supp_Table_2
Deciphering lung adenocarcinoma evolution and the role of LINE-1 retrotransposition.
Zhang T et al.
Biorxiv : the Preprint Server for Biology, 2025
40161734 (PubMed )
Supplement: media-2.xlsx › Supplementary_Table_4
RNA-SSNV: A Reliable Somatic Single Nucleotide Variant Identification Framework for Bulk RNA-Seq Data.
Long Q et al.
Frontiers in Genetics, 2022
35846154 (PubMed )
Supplement: Table6.XLSX › GBM
MET D1228N and D1246N are the Same Resistance Mutation in MET Exon 14 Skipping.
Tsai JM et al.
The Oncologist, 2021
Identification of neoantigen-reactive T lymphocytes in the peripheral blood of a patient with glioblastoma.
Leko V et al.
Journal for Immunotherapy of Cancer, 2021
34266885 (PubMed )
Supplement: jitc-2021-002882supp001.pdf
SETD2 mutations in primary central nervous system tumors.
Viaene AN et al.
Acta Neuropathologica Communications, 2018
Mutational landscape and significance across 12 major cancer types.
Kandoth C et al.
Nature, 2013
24132290 (PubMed )
Supplement: 41586_2013_BFnature12634_MOESM82_ESM.zip › nature12634-s1 › Supplementary_Table_5.xlsx › S_Table_5
Molecular Neuropathology in Practice: Clinical Profiling and Integrative Analysis of Molecular Alterations in Glioblastoma.
Nasrallah MP et al.
Academic Pathology, 0
31206012 (PubMed )
Supplement: Supplementary_Table_2__1_.xlsx › table_egfrviii_and_solid_panel_
Select a paper to view details